Related Experiment Video

Updated: Jun 6, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Beyond chemotherapy: new agents for targeted treatment of lymphoma

Anas Younes1

  • 1Department of Lymphoma and Myeloma, Unit 429, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. ayounes@mdanderson.org

Nature Reviews. Clinical Oncology
|December 15, 2010
PubMed

Insights

Advances in understanding cancer cell biology offer new lymphoma therapeutic targets. Future drug development needs focus on molecular defects, biomarkers, and faster drug approval to improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Improved understanding of cancer cell growth, survival mechanisms, and the tumor microenvironment, particularly in lymphoma.
  • Identification of numerous potential therapeutic targets based on molecular insights.

Purpose of the Study:

  • To review the current development status of novel agents for lymphoma.
  • To discuss strategies for accelerating lymphoma drug development and approval.

Main Methods:

  • Literature review of current research and clinical trials for novel lymphoma therapies.
  • Analysis of challenges and opportunities in lymphoma drug discovery.

Main Results:

  • Despite advances in molecular understanding, lymphoma drug development remains slow and unfocused.
  • Several novel agents are in various stages of development.

Conclusions:

  • Future lymphoma research must prioritize targeting 'driver' molecular defects and identifying predictive biomarkers.
  • Streamlining drug prioritization and approval processes is crucial to accelerate therapeutic advancements for lymphoma patients.

More Related Videos

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...